JPRN-UMIN000049855
Recruiting
未知
Multicenter phase II clinical trial of preoperative chemotherapy and hyperbaric oxygen therapy for resectable pancreatic cancer - Preoperative therapy (chemotherapy and hyperbaric oxygen therapy) for resectable pancreatic cancer
Division of Surgery National Hospital Organization Higashi-Ohmi General Medical Center0 sites27 target enrollmentJanuary 4, 2023
ConditionsResectable pancreatic cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Resectable pancreatic cancer
- Sponsor
- Division of Surgery National Hospital Organization Higashi-Ohmi General Medical Center
- Enrollment
- 27
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) pulmonary fibrosis or interstitial pneumonitis 2\) frequent watery diarrhea that is resistant to treatment 3\) active double cancer 4\) distant metastasis 5\) R2 resection 6\) prior anti\-cnacer therapy 7\) pregnancy 8\) a history of spontaneous pneumothorax, bronchial asthma, open\-heart surgery, etc., and who are at risk of acute ventilation failure 9\) ophthalmic treatment/after surgery (when intraocular pressure gas C3F8, SF6 is used for retinal detachment, etc.) 10\) Difficult to tolerate radical surgery 11\) Have an active infectious disease (fever 38\.0 degrees or higher) 12\) those who do not have sufficient judgment to obtain consent for this research
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.Resectable liver metastasis from colorectal cancerJPRN-UMIN000003783Hiroshima Surgical study group of Clinical Oncology81
Active, not recruiting
Phase 1
Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence. - ACCRA-HThis trial includes Patients with locally advanced squamous cell carcinoma of the head and neck (SCCH&N). In SCCH administration of chemotherapy of 5-FU and Cisplatin is a standard therapy. Herel the additional administration of cetuximab and radiotherapy under prior tumor resection is tested. Both therapies are each authorised therapies. The safety and efficacy of the combined therapies, especially on locregional recurrence of squamous cell carcinoma, will be evaluated.MedDRA version: 12.0Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-002659-17-DEHeinrich-Heine-Universität Düsseldorf
Completed
Phase 2
A multicenter phase II trial of pre-operative chemotherapy with Gemcitabine/ Cisplatin /S-1 for biliary tract cancers with lymph node metastasis diagnosed by FDG-PETbiliary tract cancersJPRN-UMIN000009831KHBO25
Completed
Not Applicable
Phase II Multicenter Clinical Trial to evaluate the immune response generation capacity and the safety of the ALVAC-HIVVCP1452 Vaccine administered alone and in combination with the MN rpg 120 / HIV-1 vaccine in humans from Brazil, Haiti, Peru and Trinidad and Tobago.-B23 Human immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in other conditionsB23PER-036-01FRED HUTCHINSON CANCER RESEARCH CENTER,
Active, not recruiting
Phase 1
A trial comparing chemotherapy and bevacizumab or lapatinib with chemotherapy alone for cancer of the stomach, oesophagus or the junction of the stomach and oesophagusPatients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma.Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0), II,III or stage IV (T4 N1orN2 M0). Lower oesophageal, Type I and II tumours should be stage II to stage IVa (T1N1, T2N1, T3N0-1, but not T2N0). T4 tumours are eligible if they involve the crura or invade the mediatinal pleural only.The tumour should be operableMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-000811-12-GBMedical Research Council Clinical Trials Unit1,100